# HEMATO-POIETIC STEM CELL THERAPY IN PSORIASIS

ONG KEAN PAN
1001130088

MASTER OF SCIENCE (ANTI-AGING, REGENERATIVE MEDICINE AND MEDICAL AESTHETIC)
FACULTY OF MEDICINE AND HEALTH SCIENCES
UCSI UNIVERSITY

2013

## ABSTRACT

Psoriasis vulgaris is a common, chronic relapsing systemic autoimmune disease that predominantly affect skin and joint with great physical and psychological impact. Despite a better understanding of pathogenesis and advancement in the treatment of psoriasis, there remains challenging especially dealing with refractory disease. Hematopoietic stem cell therapy (HSCT) has emerged as an evolving immunotherapy for several severe autoimmune diseases, including psoriasis and psoriatic arthritis. This has shed a limelight to the management of psoriasis. The aim of systematic search was to review the efficacy and safety profiles of HSCT in psoriasis. A comprehensive search using the PubMed, Ovid medicine and Cochrane review were conducted in the English language to identify all previously reported cases of psoriasis undergone HSCT. The cases transplanted for conventional indications and with coincidental psoriasis were reviewed. A total of 19 articles were included for analysis. The 24 cases of autologous and allogeneic HSCT done not purely for psoriasis indication had shown to be of benefit resulting in remission of the disease, especially the allo-HSCT group, with longer remission of psoriasis. HSCT has become safer alternative treatment for refractory psoriasis and psoriatic arthropathy. However, care should be taken to appropriately select the suitable candidates, given the fact that this procedure especially the allo-HSCT does carry significant morbidity and mortality. Protocol design including conditioning regimen, patient selection, stem cell source and final outcome are likely to be disease specific. Further studies are needed to explore these aspects. There was no enough evidence to date to make the recommendation to use HSCT as treatment of choice for psoriasis.